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Abstract
When the rate of bone resorption exceeds that of bone formation,
destruction of bone tissue occurs, resulting in a fragile skeleton. The
clinical consequences, namely osteoporosis and fragility fractures,
are common and costly problems. Treatments that normalize the
balance of bone turnover by inhibiting bone resorption preserve
bone mass and reduce fracture risk. The discovery of receptor
activator of nuclear factor-κB ligand (RANKL) as a pivotal regulator
of osteoclast activity provides a new therapeutic target. Early
studies have demonstrated that denosumab, an investigational,
highly specific anti-RANKL antibody, rapidly and substantially
reduces bone resorption. Pharmacokinetics of the antibody allow
dosing by subcutaneous injection at an interval of 6 months.
Inhibiting RANKL appears to be a promising new treatment for
osteoporosis and related disorders. More information about the
effectiveness of denosumab in reducing fracture risk, its tolerability
and safety, and the response to discontinuing therapy will be
provided by ongoing clinical studies.
Introduction
Osteoporosis is a disorder of impaired bone strength that
results in skeletal fragility and increased fracture risk [1]. It is a
common and costly disorder, and is associated with
significant morbidity and mortality [2]. About 10 million
American adults have osteoporosis, and a further 34 million
have low bone density, many of whom are at increased risk for
fracture [3]. More than 1.5 million osteoporotic fractures occur
in the USA each year. This results in more than half a million
hospitalizations, more than 800,000 emergency room
encounters, more than 2,600,000 physician office visits, and
the placement of nearly 180,000 individuals in nursing homes.
Painful vertebral fractures are the most common complication
of osteoporosis, accounting for about half of fractures. Height
loss, kyphosis, back pain, and impaired physical and
psychological function occur following such fractures [4].
Having a spine fracture is the strongest risk factor for having
another fracture of either hip or spine [5]. Hip fractures are
the most devastating type of fracture, accounting for about
300,000 hospitalizations each year and an excess mortality of
about 20% [3]. One-third of hip fractures occur in men. A
healthy 50-year-old woman has a 40% to 50% chance of
experiencing an osteoporosis-related fracture over the
remainder of her lifetime, whereas approximately 20% of men
will experience fragility fractures.
Caring for patients with these fractures is expensive; the
annual direct care expenditure on caring for patients with
osteoporotic fractures was US$12 to 18 billion in 2002 [3].
The incidence of fractures increases progressively with
advancing age. Furthermore, as the global population grows
older, the number of fractures is expected to double or triple
by the year 2050, resulting in increased costs both to
individuals and to society [6].
Pathophysiology of bone loss and fractures
Bone mass accumulates during the first two decades of life.
In healthy persons, peak bone mass is influenced primarily by
genetic factors and body size [7]. Illnesses or nutritional
deficiency during childhood and reduced exposure to sex
steroids during adolescence often blunt the acquisition of
peak bone mass, predisposing to osteoporosis in later life.
After the completion of skeletal growth, bone health is main-
tained by the coupled processes of bone resorption and
bone formation, together called bone remodeling [8]. Old or
damaged bone is removed and replaced by healthy bone. In
young adults these processes are balanced, and skeletal
renewal occurs without significant change in bone mass.
Various diseases, drugs, and metabolic abnormalities
adversely affect bone health and contribute to the develop-
ment of osteoporosis. Activation of osteoclastic bone
resorption is a common factor in the pathogenesis of bone
loss and fractures [9]. Estrogen deficiency at menopause or
androgen deficiency in men results in an unbalanced increase
in bone turnover, such that bone resorption exceeds bone
formation. Relatively rapid bone loss occurs and is accom-
panied by destruction of bone microarchitecture [10]. In older
Review
Role of RANKL inhibition in osteoporosis
Michael McClung
Oregon Osteoporosis Center, NE Hoyt Street, Portland, Oregon 97213, USA
Corresponding author: Michael McClung, mmcclung@orost.com
Published: 29 June 2007 Arthritis Research & Therapy 2007, 9(Suppl 1):S3 (doi:10.1186/ar2167)
This article is online at http://arthritis-research.com/content/9/S1/S3
© 2007 BioMed Central Ltd
BMD = bone mineral density; BSAP = bone-specific alkaline phosphatase; CTX = C-telopeptide; NTX = N-telopeptide; OPG = osteoprotegerin;
RANK = receptor activator of nuclear factor-κB; RANKL = receptor activator of nuclear factor-κB ligand.Page 2 of 6
(page number not for citation purposes)
Arthritis Research & Therapy    Vol 9 Suppl 1 McClung
adults vitamin D deficiency is common; it impairs calcium
absorption and induces secondary hyperparathyroidism, in
turn resulting in bone loss and increased fracture risk [11].
Low bone mineral density (BMD) is an important risk factor
for fractures. For every standard deviation decrease in age-
adjusted BMD, the relative risk for fracture increases by 1.5-
fold to 2.5-fold [12]. The relationship between BMD and
fracture risk is strongly modulated by age and other clinical
risk factors such as prior fracture history, lifestyle factors, and
frailty [13]. Estimates of fracture probability, made by
combining bone density and clinical risk factors, can be used
to identify patients for whom therapy would be appropriate.
Treatment of osteoporosis
The primary objective of treating patients with or who are at
risk for osteoporosis is to reduce the likelihood of new
fractures, and effective therapies exist. The use of calcium
and vitamin D supplements in older adults and hip protectors
in fall-prone elderly patients have been shown to reduce
fracture risk [14,15]. However, bone-strengthening osteo-
porosis drugs are the most effective therapies. The anti-
resorptive (anticatabolic) drugs estrogen, raloxifene, and
bisphosphonates effectively prevent bone loss in post-
menopausal women without osteoporosis [16-18]. Treatment
with either an antiresorptive drug or teriparatide, an anabolic
agent, preserves or improves bone mass and substantially
reduces fracture risk in postmenopausal women and men
with osteoporosis [19]. In the clinical trial setting, bisphos-
phonates, raloxifene, and teriparatide reduced the incidence
of new vertebral fractures by about 50% and the incidence of
multiple spine fractures by 75% to 95% [20-23]. Bisphos-
phonates and teriparatide reduce the incidence of non-
vertebral fracture, and both alendronate and risedronate
decrease the incidence of hip fracture in postmenopausal
women with osteoporosis by about 50% [20,24]. The
potential to achieve additive effects by combining a potent
antiresorptive agent such as alendronate with a bone-forming
drug such as teriparatide has not yet been realized [25,26].
The anabolic effects of teriparatide, assessed by changes in
bone density, biochemical indices of bone turnover, and bone
histomorphometry, were blunted when the agent was
administered concurrently with alendronate.
In general these therapies are well tolerated. The effective-
ness of treatment in clinical practice is limited by real or
perceived intolerance, and especially by poor adherence to
therapy, because most patients discontinue treatment before
the end of the first year [27,28].
Rationale for RANKL inhibitors to treat
osteoporosis
Receptor activator of nuclear factor-κB (RANK) is a member
of the tumor necrosis factor family expressed by osteoclasts
and their precursors [29]. The interaction of RANK with its
ligand (RANKL) has been identified as the final common
pathway through which bone resorption is regulated [29]. By
binding to its receptor RANK on osteoclastic precursors,
RANKL controls the differentiation, proliferation, and survival
of osteoclasts. Osteoprotegerin (OPG) is the natural inhibitor
of RANKL. Mice that are deficient in OPG exhibit osteo-
porosis, whereas over-expression of OPG in mice results in
reduced numbers of osteoclasts and high bone mass
[30,31]. Perturbations in the ratio of OPG to RANKL have
been demonstrated to occur with estrogen deficiency,
hyperparathyroidism, and other disorders that stimulate bone
resorption [32-34]. RANKL is also expressed by lymphocytes
and synovial fibroblasts and may mediate bone loss
associated with inflammatory conditions [35,36]. The discovery
of the RANK/RANKL/OPG pathway and its implications in the
pathogenesis of osteoporosis provides a molecular target for
new therapies to improve bone health. RANK and RANKL are
expressed by endothelial cells and lymphocytes, and this
pathway may have importance in cardiovascular diseases and
immune function [37].
Preclinical studies
Studies in animals have evaluated the effects of administering
recombinant OPG or OPG fused to immunoglobulin Fc
fragments (to increase the half-life of OPG). The osteopenia
observed in OPG-deficient mice was reversed by injections
of the OPG-Fc fusion protein or by introducing the OPG
gene using an adenovirus expression vector [38,39]. Post-
oophorectomy bone loss in rats was prevented or reversed
by administration of OPG-Fc fusion protein [40,41]. This
treatment quickly and potently inhibited indices of bone
resorption, and was associated with normal bone histology
and significant improvement in bone strength. OPG therapy
prevented bone loss in immobilized rats [42].
A preliminary report by Kostenuik and his colleagues,
presented at the European Congress on Clinical and
Economic Aspects of Osteoporosis in 2005 [43], described
the effects of treating intact female cynomologous monkeys
with OPG-Fc for 6 months. Urinary N-telopeptide (NTX), a
marker of bone resorption, was reduced by about 90%. This
was accompanied by improvements in bone mass in both the
trabecular and cortical compartments of the distal radius and
proximal tibia, as measured by peripheral quantitative
computed tomography. Cortical bone mineral content
increased, as compared with the control group, by 269% in
the distal radius and 67% in the proximal tibia with OPG
therapy. Cortical thickness increased by 251% and 39% in
the radius and tibia, respectively. This increase in cortical
thickness was the result of both a decrease in the resorption
of the inner surface of the cortex (decreased endosteal
circumference of 40% with treatment) and either enhanced
deposition or decreased resorption of bone on the outer
surface (increased periosteal circumference of 20%). As a
result of both the increase in bone mineral content and the
increase in cortical thickness and diameter, a calculated index
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compared with control animals. These effects on cortical
bone structure are substantially greater than have been
observed with other antiresorptive agents.
At the 2006 Meeting of the American Society for Bone and
Mineral Research, the same group reported the effects of
inhibiting RANKL with an anti-RANKL antibody in estrogen-
deficient older monkeys [44]. Therapy for up to 16 months
prevented loss of cancellous bone and preserved indices of
bone strength. Combining OPG therapy with parathyroid
hormone resulted in greater increases in BMD and bone
strength in rats than was achieved with either treatment alone
[45,46].
Clinical experience with RANKL inhibitors
Osteoprotegerin
To evaluate the concept that inhibition of RANKL could have
clinical utility, 52 healthy postmenopausal women were given
single doses of Fc:OPG of 0.1. 0.3, 1.0, and 3.0 mg/kg in a
phase I, randomized, placebo-controlled study [47]. The
women were followed for 84 days to determine the effects of
OPG therapy on urinary NTX (a specific marker of bone
resorption) and bone-specific alkaline phosphatase (BSAP;
an index of bone formation). Within 12 hours, a dose-
dependent decrease in NTX/creatinine ratio was observed.
Decreases of 70% to 80% occurred within 5 days with the
highest doses. NTX/creatinine values returned to baseline
within several weeks. Significant decreases in BSAP levels
were observed with the two higher doses. Inhibition of BSAP
occurred more slowly, reaching a nadir at 60 days in the 3.0
mg/kg group of about 30% below baseline. No serious or
severe adverse events were reported. A transient neutralizing
antibody to OPG was observed in one patient, without
obvious clinical effects.
These data provide evidence that inhibition of RANKL, in this
case by its natural inhibitor OPG, can have clinically
measurable effects. However, the development of OPG as a
therapy for osteoporosis was not pursued because of its
potential immunogenicity, because immunologic resistance to
OPG could have substantial untoward effects on the skeleton.
Anti-RANKL antibody
Denosumab (formerly called AMG 162) is a fully human IgG2
monoclonal antibody that binds with high affinity to human
RANKL and blocks binding of RANKL to RANK [48].
Compared with OPG, denosumab binds RANKL more
specifically (it is less likely to affect the immune and other
regulatory systems), it does not have the potential for
autoimmunization against a vital regulatory protein, and it has
a longer half-life, which permits less frequent dosing [48].
Each of these attributes makes denosumab a more attractive
therapeutic agent than forms of OPG.
Single doses of denosumab ranging from 0.01 to 3.0 mg/kg
were administered by subcutaneous injection to 49 healthy
postmenopausal women in a phase I study conducted to
evaluate safety, pharmacokinetics, and effects on bone
resorption [48]. Pharmacokinetics were nonlinear with dose.
A prolonged absorption phase occurred, with maximum
serum concentrations being reached between 5 and 21 days
after dosing. Disappearance from serum occurred in two
phases: a slow phase with half-life ranging from about
20 days at lower doses to about 32 days at higher doses.
Below circulating levels of about 1,000 ng/ml, denosumab
disappeared more rapidly. Urinary NTX levels were reduced
within 12 hours of dosing. The magnitude of the initial
response differed only modestly among the doses, but the
duration of the effect was dose related, as predicted from the
pharmacokinetic data. With a dose of 1 mg/kg (approximately
60 mg in an average size woman), inhibition of bone
resorption was sustained for at least 6 months. A return of
NTX levels toward baseline was observed with all of the
doses by the end of the 9-month follow-up period. Serum
levels of BSAP remained stable for the first 2 weeks and then
decreased in a dose-dependent manner, suggesting that the
effect on bone formation is an indirect effect. The drug
appeared to be well tolerated, with two mild injection site
reactions reported. No changes were noted in circulating
numbers of white blood cells, T or B lymphocytes, immuno-
globulins, or coagulation factors.
Encouraged by these results, 412 postmenopausal women
with low BMD were enrolled in a phase II, randomized, double-
blind, placebo-controlled, dose-ranging trial conducted to
determine the effect of denosumab on lumbar spine BMD
[49]. The women received subcutaneous injections of placebo
or denosumab doses of 6, 14, or 30 mg every 3 months, or
14, 60, 100, or 210 mg every 6 months. A separate group
was randomly assigned to receive open-label oral alendronate
70 mg once weekly. Treatment groups included 41 to 54
women. All women received calcium 1000 mg and vitamin D
400 IU daily. The study was planned to last for 2 years, with
the primary analysis scheduled after 12 months.
After 12 months, BMD in the lumbar spine, measured by
dual-energy X-ray absorptiometry, increased similarly in all
treatment groups except for the group receiving the smallest
6-monthly dose of denosumab (14 mg) [49]. The average
increase was 4.6% in women who received denosumab
60 mg every 6 months or alendronate, as compared with a
decrease of 0.8% in the placebo group (P < 0.0001 versus
placebo; Figure 1). BMD responses in regions of the proximal
femur and total body were at least as great with all but the
lowest dose of denosumab compared with alendronate. In
the distal radius, a modest increase in BMD occurred with
denosumab at 60 mg every 6 months (1.3%), whereas values
decreased by 0.5% with alendronate and by 2% in the
placebo group (Figure 1).
Biochemical indices of bone resorption (serum C-telopeptide
[CTX] and urinary NTX) and bone formation (BSAP) were
Available online http://arthritis-research.com/content/9/S1/S3measured at 3 days and at monthly intervals after the initial
dose [49]. At 3 days, median levels of serum CTX were
reduced by 68% to 83%, and urinary NTX fell by 48% to
61% from baseline values in the denosumab treatment
groups. Resorption marker values approached or had
reached their nadir at 1 month. At this time, CTX values had
decreased from baseline by 85% to 88% with all doses of
denosumab, by 62% with alendronate, and by 4% in the
placebo group. No differences were noted in initial response
between denosumab doses, but the duration of inhibition of
bone resorption was dose dependent; larger doses induced
longer responses than did smaller doses. At least partial
reversal of inhibition of bone resorption was observed with all
but the largest dose of denosumab before the second doses
were administered at 3 or 6 months. Similar responses of
bone resorption markers were observed with subsequent
dosing. Serum BSAP levels did not change during the first
month after dosing, and then gradually decreased in all
treatment groups to about 60% below baseline values. No
differences were observed in the magnitude or timing of
BSAP responses among the groups receiving denosumab
and that receiving alendronate.
A transient decrease in serum calcium and a concomitant rise
in serum parathyroid hormone typically occurs within the first
few weeks after administration of a potent anti-resorptive
agent. This was observed both in the groups receiving
denosumab and in those receiving alendronate [49]. In six
women who received denosumab (1.9%), the albumin-
adjusted serum calcium value fell below the reference range.
None of the women experienced symptoms of hypocalcemia,
and values spontaneously returned to the normal range.
Denosumab was well tolerated [49]. The frequency of
adverse experiences was similar among all treatment groups,
and there was no evidence of a dose-response effect of
denosumab for any set of adverse experiences. Two mild and
transient injection site reactions occurred. Because RANKL is
expressed in lymphocytes, special attention was given to
evaluation of immune function. No clinical or laboratory
evidence of an adverse effect on the immune system was
noted. Two women developed transient non-neutralizing anti-
denosumab antibodies. In neither woman did the antibody
appear to alter therapeutic effectiveness. Unlike the potential
for skeletal harm with anti-OPG antibodies, immunologic
resistance to denosumab would not adversely affect the
skeleton but would simply render the drug ineffective.
Preliminary results of the second year of this study were
presented at the 6th European Congress on Clinical and
Economic Aspects of Osteoporosis and Osteoarthritis in
March 2006 [50]. Therapeutic effectiveness persisted.
Increases in BMD were maintained or improved. The patterns
of inhibition of bone resorption markers following doses
administered during the second year were identical to those
observed during the first year. No tolerability or safety
concerns were identified during the second year.
Extensions of the phase II study will evaluate safety for longer
treatment periods and will provide information about the
extent of reversibility following discontinuation of treatment.
Doses of 30 mg every 3 months and 60 mg every 6 months
appeared be the best suited for clinical use. Because of the
potential to improve long-term adherence to therapy with less
frequent dosing, 60 mg every 6 months has been selected for
further development for the treatment of osteoporosis. Phase
III studies are underway to evaluate the effectiveness of
denosumab in reducing fracture risk in postmenopausal
women with osteoporosis and in preventing bone loss in
women without osteoporosis. These studies are substantially
larger than the phase II study and will provide much more
information about the safety and tolerability of denosumab.
Additional studies will determine the effectiveness of
denosumab in treating patients with osteoporosis induced by
drug treatment, including glucocorticoid therapy, aromatase
inhibitors (in women with breast cancer), and inhibitors of
gonadotropin secretion (in men with prostate cancer).
Conclusion
Inhibiting RANKL with a highly specific antibody significantly
affects bone metabolism and appears to be a promising treat-
ment for osteoporosis and other bone diseases characterized
by increased bone turnover. In addition to documenting and
quantifying the efficacy of denosumab therapy in large
numbers of patients, it will be important to monitor potential
effects on the cardiovascular and immune systems.
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Figure 1
Changes in bone mineral density with denosumab, alendronate, and
placebo. Shown here are mean percentage changes from baseline at
12 months in bone mineral density at the lumbar spine, total hip region,
and distal third of the radius in women who received placebo (open
bars), denosumab 60 mg every 6 months (solid bars), and alendronate
70 mg once weekly (stippled bars) [46]. *P < 0.001 versus placebo;
**P < 0.05 versus placebo; ‡nominal P < 0.01 versus alendronate. SE,
standard error.Acknowledgements
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